Close Menu

NEW YORK – Fulgent Genetics priced after the close of the market on Wednesday a public offering of approximately 2.3 million shares of its common stock at $11.25 per share.

The genetic testing firm said it expects gross proceeds of approximately $26.2 million and will use the funds for working capital and general corporate purposes.

Piper Jaffray is acting as sole book-running manager and BTIG is acting as lead manager on the offering. The Temple City, California-based company said it is granting the underwriters a 30-day option to purchase up to 348,750 additional shares.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.